This Project Grant award from the National Cancer Institute (CFDA 93.398 - Cancer Research Manpower) in the amount of $151,856 supports research to investigate the connection between a hyperactive thrombotic state and immunosuppression in glioblastoma (GBM), the most common primary malignant brain tumor. The research aims to 1) determine how GBM drives platelet hyperactivity and its impact on tumor growth, and 2) explore how the thrombin-PAR4 signaling axis regulates T cell function in a sex-dependent manner to enhance the immunosuppressive tumor microenvironment. This work will be conducted by researchers at the Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, with the goal of providing new insights into the mechanisms linking cancer-related thrombosis and tumor progression, as well as identifying potential therapeutic targets. The award period runs from December 16, 2024 to November 30, 2027.
Generated 3/25/25, 3:04 AM